1.Hepatic abscess mimicking hepatocellular carcinoma in a patient with alcoholic liver disease.
Jin Woong KIM ; Sang Soo SHIN ; Suk Hee HEO ; Hyo Soon LIM ; Young Hoe HUR ; Jo Heon KIM
Clinical and Molecular Hepatology 2013;19(4):431-434
No abstract available.
Aged
;
Antigens, Tumor-Associated, Carbohydrate/blood
;
Carcinoma, Hepatocellular/radiography
;
Humans
;
Liver Abscess/*complications/pathology/*radiography
;
Liver Diseases, Alcoholic/*complications/*pathology
;
Liver Neoplasms/radiography
;
Magnetic Resonance Imaging
;
Male
;
Tomography, X-Ray Computed
2.A sclerosing hemangioma of the liver.
Ji Soo SONG ; Yo Na KIM ; Woo Sung MOON
Clinical and Molecular Hepatology 2013;19(4):426-430
No abstract available.
Female
;
Hemangioma/*pathology/radiography
;
Humans
;
Liver Diseases/*pathology/radiography
;
Middle Aged
;
Positron-Emission Tomography
;
Tomography, X-Ray Computed
3.Three cases of glycogenic hepatopathy mimicking acute and relapsing hepatitis in type I diabetes mellitus.
Jae Hwang CHA ; Sang Ho RA ; Yu Mi PARK ; Yong Kwan JI ; Ji Hyun LEE ; So Yeon PARK ; Soon Koo BAIK ; Sang Ok KWON ; Mee Yon CHO ; Moon Young KIM
Clinical and Molecular Hepatology 2013;19(4):421-425
Glycogenic hepatopathy (GH) is an uncommon cause of serum transaminase elevation in type I diabetes mellitus (DM). The clinical signs and symptoms of GH are nonspecific, and include abdominal discomfort, mild hepatomegaly, and transaminase elevation. In this report we describe three cases of patients presenting serum transaminase elevation and hepatomegaly with a history of poorly controlled type I DM. All of the cases showed sudden elevation of transaminase to more than 30 times the upper normal range (like in acute hepatitis) followed by sustained fluctuation (like in relapsing hepatitis). However, the patients did not show any symptom or sign of acute hepatitis. We therefore performed a liver biopsy to confirm the cause of liver enzyme elevation, which revealed GH. Clinicians should be aware of GH so as to prevent diagnostic delay and misdiagnosis, and have sufficient insight into GH; this will be aided by the present report of three cases along with a literature review.
Acute Disease
;
Adult
;
Alanine Transaminase/blood
;
Aspartate Aminotransferases/blood
;
Delayed Diagnosis
;
Diabetes Mellitus, Type 1/complications/*pathology
;
Diagnostic Errors
;
Female
;
Glycogen Storage Disease/complications/*diagnosis/ultrasonography
;
Hepatitis/diagnosis
;
Hepatomegaly/complications/*diagnosis/ultrasonography
;
Humans
;
Liver/pathology
;
Recurrence
;
Young Adult
4.Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome.
Hae Rim KIM ; Young Sun LEE ; Hyung Joon YIM ; Hyun Joo LEE ; Ja Young RYU ; Hyun Jung LEE ; Eileen L. YOON ; Sun Jae LEE ; Jong Jin HYUN ; Sung Woo JUNG ; Ja Seol KOO ; Rok Sun CHOUNG ; Sang Woo LEE ; Jai Hyun CHOI
Clinical and Molecular Hepatology 2013;19(4):417-420
Terlipressin is a vasopressin analogue that is widely used in the treatment of hepatorenal syndrome or variceal bleeding. Because it acts mainly on splanchnic vessels, terlipressin has a lower incidence of severe ischemic complications than does vasopressin. However, it can still lead to serious complications such as myocardial infarction, skin necrosis, or bowel ischemia. Herein we report a case of severe ischemic bowel necrosis in a 46-year-old cirrhotic patient treated with terlipressin. Although the patient received bowel resection, death occurred due to ongoing hypotension and metabolic acidosis. Attention should be paid to patients complaining of abdominal pain during treatment with terlipressin.
Bilirubin/blood
;
Creatinine/blood
;
Electrocardiography
;
Fatal Outcome
;
Hepatorenal Syndrome/*drug therapy
;
Humans
;
Intestinal Mucosa/pathology
;
Intestines/surgery
;
Liver Cirrhosis/diagnosis/therapy
;
Lypressin/adverse effects/*analogs & derivatives/therapeutic use
;
Male
;
Middle Aged
;
Necrosis/*chemically induced/surgery
;
Tomography, X-Ray Computed
;
Vasoconstrictor Agents/*adverse effects/*therapeutic use
5.HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data.
Jeong Han KIM ; Yun Jung CHOI ; Hee Won MOON ; Soon Young KO ; Won Hyeok CHOE ; So Young KWON
Clinical and Molecular Hepatology 2013;19(4):409-416
BACKGROUND/AIMS: Quantification of the hepatitis B surface antigen (HBsAg) is increasingly used to determine the treatment response in patients with chronic hepatitis B (CHB). However, there are limited data about the clinical implications of Quantification of HBsAg long-term nucleoside analogue treatment for CHB. We investigated the clinical correlation between HBsAg level and clinical course in patients with CHB who are treated long-term with nucleoside analogues. METHODS: Patients with CHB who started lamivudine or entecavir monotherapy before June 2007 were enrolled. HBsAg was quantified at baseline, at 6 months, and at 1, 2, 3, 4, and 5 years of treatment. We compared data between the groups according to the presence or absence of a virological response (VR) and resistance. RESULTS: Forty-eight patients were analyzed. There was no definite reduction in HBsAg level during the early period of treatment; differences in HBsAg levels between baseline and each time point were significant only at 5 years (P=0.028). In a subgroup analysis, this difference was significant only in non-resistant patients at 5 years (P=0.041). CONCLUSIONS: There was no definite decrease in the HBsAg level during the early period of nucleoside analogue treatment, with long-term treatment being required to observe a significant reduction.
Adult
;
Aged
;
Antiviral Agents/*therapeutic use
;
DNA, Viral/blood
;
Drug Resistance, Viral/genetics
;
Female
;
Follow-Up Studies
;
Guanine/*analogs & derivatives/therapeutic use
;
Hepatitis B Surface Antigens/*blood
;
Hepatitis B, Chronic/*drug therapy
;
Humans
;
Lamivudine/*therapeutic use
;
Male
;
Middle Aged
;
Retrospective Studies
6.Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B.
Sang Hoon AHN ; Ji Yong CHUN ; Soo Kyung SHIN ; Jun Yong PARK ; Wangdon YOO ; Sun Pyo HONG ; Soo Ok KIM ; Kwang Hyub HAN
Clinical and Molecular Hepatology 2013;19(4):399-408
BACKGROUND/AIMS: Molecular diagnostic methods have enabled the rapid diagnosis of drug-resistant mutations in hepatitis B virus (HBV) and have reduced both unnecessary therapeutic interventions and medical costs. In this study we evaluated the analytical and clinical performances of the HepB Typer-Entecavir kit (GeneMatrix, Korea) in detecting entecavir-resistance-associated mutations. METHODS: The HepB Typer-Entecavir kit was evaluated for its limit of detection, interference, cross-reactivity, and precision using HBV reference standards made by diluting high-titer viral stocks in HBV-negative human serum. The performance of the HepB Typer-Entecavir kit for detecting mutations related to entecavir resistance was compared with direct sequencing for 396 clinical samples from 108 patients. RESULTS: Using the reference standards, the detection limit of the HepB Typer-Entecavir kit was found to be as low as 500 copies/mL. No cross-reactivity was observed, and elevated levels of various interfering substances did not adversely affect its analytical performance. The precision test conducted by repetitive analysis of 2,400 replicates with reference standards at various concentrations showed 99.9% agreement (2398/2400). The overall concordance rate between the HepB Typer-Entecavir kit and direct sequencing assays in 396 clinical samples was 99.5%. CONCLUSIONS: The HepB Typer-Entecavir kit showed high reliability and precision, and comparable sensitivity and specificity for detecting mutant virus populations in reference and clinical samples in comparison with direct sequencing. Therefore, this assay would be clinically useful in the diagnosis of entecavir-resistance-associated mutations in chronic hepatitis B.
Adult
;
Antiviral Agents/*therapeutic use
;
Cross Reactions
;
DNA, Viral/blood/standards
;
Drug Resistance, Viral/*genetics
;
Genotype
;
Guanine/*analogs & derivatives/therapeutic use
;
Hepatitis B virus/genetics
;
Hepatitis B, Chronic/*drug therapy/genetics
;
Humans
;
Mutation
;
Polymerase Chain Reaction/standards
;
Reagent Kits, Diagnostic/*standards
;
Reference Standards
;
Sequence Analysis, DNA
;
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/standards
7.Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis.
Kyoung Min MOON ; Gaeun KIM ; Soon Koo BAIK ; Eunhee CHOI ; Moon Young KIM ; Hyoun A KIM ; Mee Yon CHO ; Seung Yong SHIN ; Jung Min KIM ; Hong Jun PARK ; Sang Ok KWON ; Young Woo EOM
Clinical and Molecular Hepatology 2013;19(4):389-398
BACKGROUND/AIMS: We compared the cirrhosis-prediction accuracy of an ultrasonographic scoring system (USSS) combining six representative sonographic indices with that of liver stiffness measurement (LSM) by transient elastography, and prospectively investigated the correlation between the USSS score and LSM in predicting cirrhosis. METHODS: Two hundred and thirty patients with chronic liver diseases (187 men, 43 women; age, 50.4+/-9.5 y, mean+/-SD) were enrolled in this prospective study. The USSS produces a combined score for nodularity of the liver surface and edge, parenchyma echogenicity, presence of right-lobe atrophy, spleen size, splenic vein diameter, and abnormality of the hepatic vein waveform. The correlations of the USSS score and LSM with that of a pathological liver biopsy (METAVIR scoring system: F0-F4) were evaluated. RESULTS: The mean USSS score and LSM were 7.2 and 38.0 kPa, respectively, in patients with histologically overt cirrhosis (F4, P=0.017) and 4.3 and 22.1 kPa in patients with fibrotic change without overt cirrhosis (F0-F3) (P=0.025). The areas under the receiver operating characteristic (ROC) curves of the USSS score and LSM for F4 patients were 0.849 and 0.729, respectively. On the basis of ROC curves, criteria of USSS > or =6: LSM > or =17.4 had a sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 89.2%:77.6%, 69.4%:61.4%, 86.5%:83.7%, 74.6%:51.9% and 0.83:0.73, respectively, in predicting F4. CONCLUSIONS: The results indicate that this USSS has comparable efficacy to LSM in the diagnosis of cirrhosis.
Adult
;
Area Under Curve
;
*Elasticity Imaging Techniques
;
Female
;
Hepatic Veins/physiopathology
;
Humans
;
Liver Cirrhosis/pathology/*ultrasonography
;
Male
;
Middle Aged
;
Odds Ratio
;
Predictive Value of Tests
;
Prospective Studies
;
ROC Curve
;
Severity of Illness Index
;
Spleen/anatomy & histology
;
Splenic Vein/physiology
8.The levels of liver enzymes and atypical lymphocytes are higher in youth patients with infectious mononucleosis than in preschool children.
Yan WANG ; Jun LI ; Yuan Yuan REN ; Hong ZHAO
Clinical and Molecular Hepatology 2013;19(4):382-388
BACKGROUND/AIMS: Infectious mononucleosis (IM) is the clinical presentation of primary infection with Epstein-Barr virus. Although the literature contains a massive amount of information on IM, most of this is related specifically to only children or adults separately. In order to distinguish any differences between preschool children and youth patients, we retrospectively analyzed their demographic and clinical features. METHODS: Records of patients hospitalized from December 2001 to September 2011 with a diagnosis of IM were retrieved from Peking University First Hospital, which is a tertiary teaching hospital in Beijing. The demographic data and clinical characteristics were collected. RESULTS: IM was diagnosed in 287 patients during this 10-year period, with incidence peaks among preschool children (< or =7 years old, 130/287, 45.3%) and youth patients (>15 and <24 years old, 101/287, 35.2%). Although the complaints at admission did not differ between these two patient groups, the incidence of clinical signs (tonsillopharyngitis, lymphadenopathy, hepatomegaly, and edema of the eyelids) was much higher in preschool children. The incidence of liver lesion and percentage of atypical lymphocytes were significantly higher in the youth group (P<0.001), and the average hospital stay was longer in this group. Pneumonia was the most common complication, and there was no case of mortality. CONCLUSIONS: The incidence of IM peaks among preschool children and youth patients in Beijing, China. The levels of liver enzymes and atypical lymphocytes increase with age.
Adolescent
;
Adult
;
Alanine Transaminase/blood
;
Aspartate Aminotransferases/blood
;
Child
;
Child, Preschool
;
Demography
;
Fever/etiology
;
Humans
;
Incidence
;
Infant
;
Infectious Mononucleosis/*diagnosis/enzymology/epidemiology/pathology
;
Liver/*enzymology
;
Lymphocytes/cytology/*immunology/metabolism
;
Pharyngitis/etiology
;
Retrospective Studies
;
Young Adult
;
gamma-Glutamyltransferase/blood
9.Predicting factors of present hepatitis C virus infection among patients positive for the hepatitis C virus antibody.
Chi Hoon LEE ; Hyun Phil SHIN ; Joung Il LEE ; Kwang Ro JOO ; Jae Myung CHA ; Jung Won JEON ; Jun Uk LIM ; Joon Ki MIN ; Dong Hee KIM ; Sung Wook KANG ; Hyun Jun JOUNG
Clinical and Molecular Hepatology 2013;19(4):376-381
BACKGROUND/AIMS: To identify the predicting factors of present hepatitis C virus (HCV) infection among patients with positivity for antibodies to HCV (anti-HCV). METHODS: We analyzed patients who showed positive enzyme immunoassay (EIA) results and performed an HCV RNA test as a confirmatory test at Kyung Hee University Hospital at Gangdong from June 2006 to July 2012. The features distinguishing the groups with positive and negative HCV RNA results were reviewed. RESULTS: In total, 490 patients were included. The results of the HCV RNA test were positive and negative in 228 and 262 patients, respectively. The index value of anti-HCV, mean age, platelet counts, total bilirubin, prothrombin time international normalized ratio, albumin and alanine transaminase (ALT) levels differed significantly between the two groups. On multivariable analysis, an index value of anti-HCV >10 [odds ratio (OR)=397.27, P<0.001), ALT >40 IU/L (OR=3.64, P=0.001), and albumin <3.8 g/dL (OR=2.66, P=0.014) were related to present HCV infection. CONCLUSIONS: Although EIA is not a quantitative test, considering the anti-HCV titer with ALT and albumin levels may be helpful in predicting present of HCV infection.
Adult
;
Aged
;
Alanine Transaminase/blood
;
Bilirubin/blood
;
Female
;
Hepacivirus/genetics
;
Hepatitis C/*diagnosis
;
Hepatitis C Antibodies/*blood
;
Humans
;
Immunoenzyme Techniques
;
Male
;
Middle Aged
;
Odds Ratio
;
Platelet Count
;
Predictive Value of Tests
;
RNA, Viral/analysis
;
Serum Albumin/analysis
10.The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
Won Ki HONG ; Moon Young KIM ; Soon Koo BAIK ; Seung Yong SHIN ; Jung Min KIM ; Yong Seok KANG ; Yoo Li LIM ; Young Ju KIM ; Youn Zoo CHO ; Hye Won HWANG ; Jin Hyung LEE ; Myeong Hun CHAE ; Hyoun A KIM ; Hye Won KANG ; Sang Ok KWON
Clinical and Molecular Hepatology 2013;19(4):370-375
BACKGROUND/AIMS: Liver stiffness measurement (LSM) has been proposed as a non-invasive method for estimating the severity of fibrosis and the complications of cirrhosis. Measurement of the hepatic venous pressure gradient (HVPG) is the gold standard for assessing the presence of portal hypertension, but its invasiveness limits its clinical application. In this study we evaluated the relationship between LSM and HVPG, and the predictive value of LSM for clinically significant portal hypertension (CSPH) and severe portal hypertension in cirrhosis. METHODS: LSM was performed with transient elastography in 59 consecutive cirrhotic patients who underwent hemodynamic HVPG investigations. CSPH and severe portal hypertension were defined as HVPG > or =10 and > or =12 mmHg, respectively. Linear regression analysis was performed to evaluate the relationship between LSM and HVPG. Diagnostic values were analyzed based on receiver operating characteristic (ROC) curves. RESULTS: A strong positive correlation between LSM and HVPG was observed in the overall population (r2=0.496, P<0.0001). The area under the ROC curve (AUROC) for the prediction of CSPH (HVPG > or =10 mmHg) was 0.851, and the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for an LSM cutoff value of 21.95 kPa were 82.5%, 73.7%, 86.8%, and 66.7%, respectively. The AUROC at prediction of severe portal hypertension (HVPG > or =12 mmHg) was 0.877, and the sensitivity, specificity, PPV, and NPV at LSM cutoff value of 24.25 kPa were 82.9%, 70.8%, 80.6%, and 73.9%, respectively. CONCLUSIONS: LSM exhibited a significant correlation with HVPG in patients with cirrhosis. LSM could be a non-invasive method for predicting CSPH and severe portal hypertension in Korean patients with liver cirrhosis.
Adult
;
Aged
;
Alcohol-Related Disorders/complications
;
Area Under Curve
;
*Elasticity Imaging Techniques
;
Female
;
Hepatitis B/complications
;
Hepatitis C/complications
;
Humans
;
Hypertension, Portal/*complications/*diagnosis
;
Linear Models
;
Liver Cirrhosis/*complications/*diagnosis/pathology
;
Male
;
Middle Aged
;
ROC Curve
;
Republic of Korea
;
Sensitivity and Specificity